Alan Talesnick

Alan Talesnick counsels clients on securities law matters, including private and public offerings, public disclosure, SEC reporting and compliance, corporate governance, and mergers and acquisitions. In addition, he works with clients regarding joint ventures, mutual collaboration, and other business agreements and transactions.

His work includes assistance in negotiating, structuring, drafting and reviewing documents, including strategy input related to these activities. Alan works closely with and provides ongoing legal advice to company management and boards of directors with respect to these matters.

Alan has represented clients ranging from listed mid-cap and micro-cap publicly-traded companies to emerging growth companies, closely-held business entities and private equity funds and investors, both on an ongoing and a transactional basis. These include companies involved in biotech and healthcare; wireless, telecommunications, software and other technology-oriented businesses; oil and gas; mining; manufacturing and other industrial sectors, investment banking; real estate; property and casualty insurance; retail and wholesale consumer products; and marketing and distribution. The publicly-reporting entities have been traded on the New York stock Exchange, American Stock Exchange, NASDAQ, OTC Bulletin Board and Pink Sheets.

Significant Representations

• Representation of a biotech and biomedical private investment entity based in the Czech Republic
• Representation of a U.S. based carbon recapture company
• Representation of a development stage publicly-traded media-entertainment company
• Representation of a New York based development stage biomedical company
• Representation of a development stage medical device company

PUBLICATIONS

Corporate Silence and Rule 10b-5: Does a Publicly Held Corporation Have an Affirmative Obligation to Disclose, 49 Denver Law Review Journal, 1973